Oculis Holding
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bahnhofstrasse 20, Zug, Zug, 6300, Switz...Phone Number
+41 417113960Website
www.oculis.comRevenue
$10.4 MillionStock Symbol
OCSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Oculis Holding
Headquartered in Zug, Switzerland with global operations in Europe, the U.S. and China. Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis' formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.Explore more
Oculis Holding Org Chart
KK
Chief Legal Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oculis Holding your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Oculis Holding recently announced quarterly report
Oculis Holding, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oculis Holding launches new products
Check out if Oculis Holding is spiking on competitors!
Click to see if Oculis Holding had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Oculis Holding
Funding: Get notified immidiatlly once Oculis Holding has new funding data
Check if Oculis Holding has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Oculis Holding as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Oculis Holding is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oculis Holding is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oculis Holding.
Oculis Holding financials insights
Gather financial insights about Oculis Holding, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$4.6M
2018
Series B
$20.5M
2021
Series C
$57M
2025
Stock/Share Issuance
$110M
Oculis Holding Tech Stack
A closer look at the technologies used by Oculis Holding
Most Recent Scoops
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Funding
Funding
Oculis Holding News & Media
Oculis Reports Q2 2026 Financial Results and Provides Company Update
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the second quarter ended June 30, 2026, and provided an overview of the Company’s progress.Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis (MS) relapses.Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis (MS) relapses.Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oculis Holding
Sign Up For FreeTo access detailed company insights
Headquartered in Zug, Switzerland with global operations in Europe, the U.S. and China. Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatmen... Read More
